Heat Shock Protein 90 (HSP90) and Her2 in Adenocarcinomas of the Esophagus

Cancers

Julia Slotta-Huspenina¹  Karl-Friedrich Becker¹  Marcus Feith²  Axel Walch³ 

[1] Institute of Pathology, Technische Universität München, München 81765, Germany; E-Mails:;Department of Surgery, Klinikum Rechts der Isar der Technischen Universität München, München 81622, Germany; E-Mail:;Institute of Pathology, Helmholtz Zentrum München, Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), Neuherberg 85764, Germany; E-Mail:

关键词: HSP90;    Her2;    esophageal adenocarcinoma;    immunohistochemistry;    RPPA;    in situ hybridization;   

DOI  :  10.3390/cancers6031382

来源: mdpi

【 摘 要 】

Her2 overexpression and amplification can be found in a significant subset of esophageal adenocarcinomas. The activity of Her2 has been shown to be modulated by molecular chaperones such as HSP90. We analyzed expression/amplification data for HSP90 and Her2 on 127 primary resected esophageal adenocarcinomas in order to evaluate a possible relationship between these two molecules. HSP90 expression determined by immunohistochemistry was observed in various levels. Thirty nine (39) tumors (30.7%) were classified as Her2-positive according to their immunoreactivity and amplification status. There was a significant correlation between HSP90 expression and Her2-status (p = 0.008). This could also be demonstrated by quantitative protein expression analysis with reverse phase protein arrays (r = 0.9; p < 0.001). Her2-status was associated withpT-category (p = 0.041), lymph node metastases (p = 0.049) and tumor differentiation (p = 0.036) with a higher percentage of cases with negative Her2 status in lower tumor stagesA negative Her2-status was also associated with better survival in univariate and multivariate analysis (p = 0.001 and p = 0.014). For HSP90, no associations between clinical and pathological parameters were found. The observed association between HSP90 expression and Her2 suggests a co-regulation of these molecules in at least a subset of esophageal adenocarcinomas. Anti-HSP90 drugs, which recently have been introduced in cancer treatment, may also be an option for these tumors by targeting HSP90 alone or in combination with Her2.

【 授权许可】

CC BY   
© 2014 by the authors; licensee MDPI, Basel, Switzerland.